Hanmi Pharmaceutical said on the 1st that it has submitted a clinical trial plan for the obesity drug HM17321 to the U.S. Food and Drug Administration (FDA). It is an obesity drug that reduces fat and increases muscle.
The company plans to evaluate safety and tolerability in a phase 1 clinical trial in healthy adults. This obesity drug can be used as a monotherapy or in combination therapy. Key study results will be presented at the Obesity Society in the United States next month. The goal is commercialization in 2031.
Choi In-young, head of the Hanmi Pharmaceutical R&D Center, said, "We will enable obesity patients to plan and maintain healthy lives over the long term," and "We will meet the needs of those with sarcopenia, older adults, and groups with reduced physical function."